Exploring the antitumor activity of curcumin in breast cancer

Phase 3

Recruiting

• Conditions: Breast cancer.; Malignant neoplasm of breast of unspecified site; C50.9

• Registration Number: IRCT20131017015044N4
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Patients with metastatic breast cancer that is measurable
Breast cancer patients who have not received any chemotherapy for metastasis
patients at the age of 25 to 70

Exclusion Criteria

History of any allergy to turmeric or its products

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival. Timepoint: One year after the treatment is completed. Method of measurement: Patient follow-up.

Secondary Outcome Measures

Name	Time	Method
Progression-free survival. Timepoint: During treatment and after it every 3 months. Method of measurement: criteria of Response evaluation criteria in solid tumors.;Anemia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Neutropenia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Thrombocytopenia. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of complete blood count.;Kidney function. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of BUN and creatinine.;Liver function. Timepoint: Before each session of monthly chemotherapy. Method of measurement: laboratory assessment of SGOT and SGPT.